JP2007534772A5 - - Google Patents

Download PDF

Info

Publication number
JP2007534772A5
JP2007534772A5 JP2007510987A JP2007510987A JP2007534772A5 JP 2007534772 A5 JP2007534772 A5 JP 2007534772A5 JP 2007510987 A JP2007510987 A JP 2007510987A JP 2007510987 A JP2007510987 A JP 2007510987A JP 2007534772 A5 JP2007534772 A5 JP 2007534772A5
Authority
JP
Japan
Prior art keywords
seq
composition
polypeptide
group
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007510987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007534772A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/014668 external-priority patent/WO2005104785A2/en
Publication of JP2007534772A publication Critical patent/JP2007534772A/ja
Publication of JP2007534772A5 publication Critical patent/JP2007534772A5/ja
Pending legal-status Critical Current

Links

JP2007510987A 2004-04-27 2005-04-27 ヒト肝細胞癌細胞を特異的に標的化するための方法および組成物 Pending JP2007534772A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56568804P 2004-04-27 2004-04-27
PCT/US2005/014668 WO2005104785A2 (en) 2004-04-27 2005-04-27 Methods and compositions for specifically targeting human hepatocellular carcinoma cells

Publications (2)

Publication Number Publication Date
JP2007534772A JP2007534772A (ja) 2007-11-29
JP2007534772A5 true JP2007534772A5 (https=) 2008-06-19

Family

ID=35242179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007510987A Pending JP2007534772A (ja) 2004-04-27 2005-04-27 ヒト肝細胞癌細胞を特異的に標的化するための方法および組成物

Country Status (4)

Country Link
US (1) US20080152650A1 (https=)
EP (1) EP1755669A4 (https=)
JP (1) JP2007534772A (https=)
WO (1) WO2005104785A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
WO2008118176A2 (en) * 2006-06-02 2008-10-02 Verenium Corporation Lase enzymes, nucleic acids encoding them and methods for making and using them
EP2388338A1 (en) * 2010-04-30 2011-11-23 Medizinische Hochschule Hannover Method for determination of and medicament for influencing the activity of the immune system
KR102318434B1 (ko) * 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
AU2020227825B2 (en) 2019-02-27 2026-03-26 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
CN114935651A (zh) * 2022-04-27 2022-08-23 广州源康生物医药科技有限公司 一种肿瘤生物标志物及应用
WO2024180461A1 (en) * 2023-02-27 2024-09-06 Ebrahiminik Hojat Integrated system for ethanol ablation and radiofrequency ablation of thyroid nodules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7549498A (en) * 1997-06-03 1998-12-21 Protegene Inc. Human proteins having transmembrane domains and dnas encoding these prot eins
EP1217066A1 (en) * 2000-12-21 2002-06-26 Universiteit Gent Modulation of ATP-binding cassette transporter activity
US20040068096A1 (en) * 2001-09-21 2004-04-08 Zenta Tsuchihashi Human single nucleotide polymorphisms in organic anion transport and multi-drug resistant proteins
AU2003209340A1 (en) * 2002-01-18 2003-09-02 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
WO2003083046A2 (en) * 2002-03-08 2003-10-09 Curagen Corporation Novel proteins and nucleic acids encoding same
CN1659287A (zh) * 2002-04-05 2005-08-24 美国政府健康及人类服务部 诊断肝癌转移或发病可能性及鉴定治疗靶点的方法

Similar Documents

Publication Publication Date Title
CA2673972C (en) Dbait and its standalone uses thereof
Chen et al. Novel strategies for the treatment of chondrosarcomas: targeting integrins
US20120171201A1 (en) Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
RU2013129450A (ru) Способ лечения опухолей с применением vegf-специфических антагонистов
WO2003034903B1 (en) Psma antibodies and protein multimers
JP2011526626A5 (https=)
JP2005523683A5 (https=)
JP2006525796A5 (https=)
JP2009540852A5 (https=)
JP2019506862A5 (https=)
JP2002505841A5 (https=)
US20160200783A1 (en) Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
CN104411825B (zh) 骨膜蛋白适配体及包含其的抗癌组合物
KR20120048613A (ko) Ｓｐａｒｃ 안티센스 조성물과 이들의 용도
JP2007534772A5 (https=)
JP2020535110A (ja) 分子誘導システムペプチド及びその使用
WO2020229429A1 (en) Bcl-2 inhibitors for use in the treatment of a bcl-2 mediated cancer carrying the gly101val mutation
JP2016520570A (ja) Ａ型インフルエンザウイルス感染の治療又は予防に使用するためのｐａｒ−４アンタゴニスト
US12162874B2 (en) Peptidomimetic-based antibody surrogate for HER2
US20100247525A1 (en) Compositions and methods for treating anthrax lethality
KR20220001481A (ko) 혈액-뇌 장벽 침투 압타머 및 이의 이용
US20160068599A1 (en) Method for treating neuroendocrine cancer
JP2022545429A (ja) がん治療のための化学療法剤とα－ラクトグロブリン－オレイン酸複合体との組合せ
WO2024145858A1 (zh) Dna-trail复合物及其治疗肿瘤的用途
JP2005522226A5 (https=)